Genetics and Heart Health after Cancer Therapy | Clinical Research Studies Listing

Recruiting

99 years or below

All

80 participants needed

1 Location

Brief description of study

The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease. We plan to enroll 100 BRCA1/2 mutation carriers who have been treated for breast cancer between 2005 and 2017. They will undergo comprehensive functional cardiovascular phenotyping (including biomarkers, echocardiogram, cardio-pulmonary exercise testing, and surveys) at enrollment and annually for five years. Additionally, our goal is to determine if human induced pluripotent stem cell lines (iPSC) from BRCA 1/2 carriers can be used to recapitulate the clinical CV phenotype, a subset of patients (n=10) will be asked to provide blood for the generation of iPSC lines.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: genetics, cancer
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 828385

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).